Although patients with other solid tumors have benefited from immune checkpoint blockade therapy targeting the PD1/PD-L1 interaction, CRC patients did not benefit until the introduction of the concept of mismatch repair (MMR) proficiency or deficiency [7, 8]. The gene discussed is PDCD1; the disease is colorectal carcinoma.